Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis
- PMID: 16495544
- PMCID: PMC1418655
- DOI: 10.1128/IAI.74.3.1718-1724.2006
Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis
Abstract
Mycobacterium bovis BCG is the only available vaccine against tuberculosis. Reasons for why diverse BCG substrains induce different levels of protection in clinical trials remain unclear. The aim of this study was to compare the effectiveness of 10 BCG substrains in a mouse model of pulmonary tuberculosis. BALB/c mice were subcutaneously vaccinated and 2 months later were challenged with Mycobacterium tuberculosis H37Rv by intratracheal injection. Two and 4 months after challenge, delayed-type hypersensitivity (DTH) response, lung tissue affected by pneumonia, CFU, T-cell counts, and cytokine expression (interleukin-2 [IL-2], IL-4, IL-10, and gamma interferon) were determined. A differential protective effect of the diverse BCG substrains was found. BCG Phipps led to the largest and most persistent reduction of CFU counts and of the area of pneumonia at 2 and 4 months after challenge. This protection was accompanied by reduced IL-10-producing T cells. Contemporary BCG substrains induce a wide range of protection in this animal model. These data can help in the selection of the best vaccine for human immunization and for the development of novel recombinant BCG-based vaccine.
Figures


Similar articles
-
A new vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis.Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):115-26. doi: 10.1016/j.tube.2004.10.004. Epub 2005 Jan 22. Tuberculosis (Edinb). 2005. PMID: 15687035
-
Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.Scand J Immunol. 2013 Dec;78(6):497-506. doi: 10.1111/sji.12116. Scand J Immunol. 2013. PMID: 24283772
-
Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis.Vaccine. 2006 Mar 20;24(13):2333-42. doi: 10.1016/j.vaccine.2005.11.051. Epub 2005 Dec 12. Vaccine. 2006. PMID: 16388878
-
[Novel vaccines against M. tuberculosis].Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
-
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.Clin Microbiol Rev. 2010 Oct;23(4):781-94. doi: 10.1128/CMR.00005-10. Clin Microbiol Rev. 2010. PMID: 20930073 Free PMC article. Review.
Cited by
-
A review of the BCG vaccine and other approaches toward tuberculosis eradication.Hum Vaccin Immunother. 2021 Aug 3;17(8):2454-2470. doi: 10.1080/21645515.2021.1885280. Epub 2021 Mar 26. Hum Vaccin Immunother. 2021. PMID: 33769193 Free PMC article. Review.
-
Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain.Clin Exp Immunol. 2007 Feb;147(2):330-8. doi: 10.1111/j.1365-2249.2006.03284.x. Clin Exp Immunol. 2007. PMID: 17223975 Free PMC article.
-
Joint effect of MCP-1 genotype GG and MMP-1 genotype 2G/2G increases the likelihood of developing pulmonary tuberculosis in BCG-vaccinated individuals.PLoS One. 2010 Jan 25;5(1):e8881. doi: 10.1371/journal.pone.0008881. PLoS One. 2010. PMID: 20111728 Free PMC article.
-
Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations.Sci Rep. 2015 Oct 21;5:15443. doi: 10.1038/srep15443. Sci Rep. 2015. PMID: 26487098 Free PMC article.
-
Mycobacterium bovis BCG vaccine strains lack narK2 and narX induction and exhibit altered phenotypes during dormancy.Infect Immun. 2008 Jun;76(6):2587-93. doi: 10.1128/IAI.01235-07. Epub 2008 Mar 24. Infect Immun. 2008. PMID: 18362135 Free PMC article.
References
-
- Abou-Zeid, C., I. Smith, J. Grange, J. Steele, and G. Rook. 1986. Subdivision of daughter strains of bacille Calmette-Guerin (BCG) according to secreted protein patterns. J. Gen. Microbiol. 132:3047-3053. - PubMed
-
- Anonymous.1978. Phenotypes of BCG-vaccines seed lot strains: results of an international cooperative study. International Union against Tuberculosis. Tubercle 59:139-142. - PubMed
-
- Anonymous.2003. WHO annual report on global TB control-summary. Wkly. Epidemiol. Rec. 78:122-128. - PubMed
-
- Behr, M. A. 2001. Correlation between BCG genomics and protective efficacy. Scand. J. Infect. Dis. 33:249-252. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources